Synthetic semaglutide: the reporting gaps

On 24 August 2026 Awadhesh Kumar Singh, Akriti Singh, and Ritu Singh published a paper in Diabetes, Obesity and Metabolism that goes straight at a question the GLP-1 boom has largely avoided: do compounded and synthetic versions of semaglutide actually back up the clinical claims made for them? The paper's answer, in brief, is no. The authors identify a set of reporting gaps that separate these products from the reference product, and they argue the gap matters clinically.^[1]

What the reference product is and what it shows

The reference semaglutide is the molecule Novo Nordisk developed, tested in large randomised controlled trials, and brought to market as Ozempic (type-2 diabetes) and Wegovy (weight management). The EMA authorised Wegovy after four pivotal studies enrolling a combined several thousand adults and adolescents. In the largest study, 1,961 patients on 2.4 mg weekly semaglutide lost an average 15% of body weight over 68 weeks versus 2% on placebo^[2]. The prescribing information lists a specific titration schedule, contraindications, boxed warnings, and post-marketing pharmacovigilance obligations. That is the evidentiary base. Compounded and synthetic products are not part of it.

What Singh et al. found lacking

The paper identifies three categories of reporting gap^[1]. First, pharmacokinetic data. The reference product's absorption, distribution, metabolism, and excretion profile was characterised across thousands of participants under controlled conditions. Synthetic versions made outside regulated pharmaceutical manufacturing do not carry equivalent pharmacokinetic characterisation. Vendors selling them sometimes assert bioequivalence to Wegovy or Ozempic, but the authors note those assertions are not supported by published comparative studies.

Second, dose-equivalence claims. The branded product's 0.25 mg to 2.4 mg titration was calibrated to the specific formulation and delivery system that went through regulatory review. A compounded version at the same nominal dose is not, on the current evidence, proven to produce the same systemic exposure. The paper treats this as a structural gap: without head-to-head pharmacokinetic data, dose-equivalence claims are extrapolations, not established facts.

Third, adverse-event surveillance. The branded products feed into Yellow Card (MHRA), EudraVigilance (EMA), and FAERS (FDA) reporting systems. The MHRA updated its safety guidance on 5 February 2026, adding a rare risk of non-arteritic anterior ischaemic optic neuropathy affecting approximately 1 in 10,000 users, based on signal detection from over 10.2 million dispensed packs^[3]. Compounded and synthetic versions sold outside those supply chains do not contribute to, or benefit from, that level of post-market signal detection.

Why clinical claims matter in this context

Vendors selling synthetic semaglutide often reproduce the STEP trial weight-loss figures (14.9% at 68 weeks in STEP-1, for instance) alongside their own product descriptions. The Singh et al. paper is, at its core, a documentation of why that practice is misleading. The trial figures come from a specific formulation, manufactured under pharmaceutical-grade conditions, titrated in a controlled research setting, and monitored by institutional safety boards. Those conditions do not transfer to a compounded or research-chemical version by virtue of shared molecular structure.

The paper stops short of claiming that synthetic semaglutide is dangerous or ineffective; it cannot, because the comparative data do not exist. What it argues is that the absence of that data is itself a clinical gap, and that vendors and practitioners who cite branded trial results in support of synthetic products are citing evidence for something other than what they are selling. That is the reporting gap the title refers to. Readers who want to understand the broader regulatory picture for semaglutide across different jurisdictions can follow the country regulation pages linked from the peptide hub.

What is not settled by this paper

The paper is a commentary and evidence review, not a head-to-head clinical trial. It does not produce new pharmacokinetic data, and it does not establish that any specific synthetic semaglutide product causes harm above the baseline rate seen in the branded trials. The authors call for direct comparative studies, not for any individual to change their clinical practice based on this paper alone. Readers considering any semaglutide product, compounded or branded, should discuss the decision with a clinician who knows their individual health history.

The MHRA's Yellow Card data and the EMA's pharmacovigilance record will continue to grow as the branded products accumulate more post-market exposure. The equivalent data stream for synthetic versions does not exist. That asymmetry is likely to become a more prominent regulatory and clinical issue as the GLP-1 market expands and as regulators tighten enforcement on compounded copies. See the semaglutide peptide page for the current regulatory timeline across the jurisdictions PeptideMethods covers.